Floatz Rating
B63/100
Confidence
Indicative
Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
64High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07358689CT.gov Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06706219CT.gov Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC | — | Not Yet Recruiting | — | — | — |
NCT07554846CT.gov Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC | — | Not Yet Recruiting | — | — | — |
NCT07493980CT.gov Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients | — | Not Yet Recruiting | — | — | — |
NCT07438600CT.gov Study of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLC | — | Not Yet Recruiting | — | — | — |
NCT07286942CT.gov Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial | — | Not Yet Recruiting | — | — | — |
NCT07169994CT.gov A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06623136CT.gov A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05798845CT.gov The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT07039656CT.gov Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell Lung Cancer With or Without Prior Neoadjuvant Therapy | — | Recruiting | — | — | — |
Show 43 more trialsShow fewer
NCT06426511CT.gov ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC | — | Recruiting | — | — | — |
NCT06709274CT.gov Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC | — | Not Yet Recruiting | — | — | — |
NCT06437977CT.gov Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH) | — | Recruiting | — | — | — |
NCT06505837CT.gov JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC） | — | Active Not Recruiting | — | — | — |
NCT06269211CT.gov Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression | — | Recruiting | — | — | — |
NCT06293690CT.gov Toripalimab Combined With SBRT for NSCLC | — | Active Not Recruiting | — | — | — |
NCT06127303CT.gov Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC | — | Recruiting | — | — | — |
NCT06984588CT.gov A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT06221670CT.gov Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK) | — | Recruiting | — | — | — |
NCT05962021CT.gov Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation | — | Not Yet Recruiting | — | — | — |
NCT05955105CT.gov A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | — | Recruiting | — | — | — |
NCT05891080CT.gov Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial | — | Not Yet Recruiting | — | — | — |
NCT05212922CT.gov A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC | — | Withdrawn | — | — | — |
NCT05842018CT.gov Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors) | — | Unknown | — | — | — |
NCT05757492CT.gov Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT06054152CT.gov CX3CR1+T Cell Predict Immunotherapy Efficacy | — | Completed | — | — | — |
NCT05800340CT.gov Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC | — | Recruiting | — | — | — |
NCT05888402CT.gov Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC | — | Active Not Recruiting | — | — | — |
NCT05386888CT.gov A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC | — | Completed | — | — | — |
NCT06065813CT.gov Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT05003037CT.gov Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT05021328CT.gov Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC | — | Completed | — | — | — |
NCT05055583CT.gov Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC | — | Unknown | — | — | — |
NCT04797702CT.gov Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small Cell Lung Cancer. | — | Unknown | — | — | — |
NCT04725448CT.gov Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma | — | Unknown | — | — | — |
NCT04772287CT.gov Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008) | — | Not Yet Recruiting | — | — | — |
NCT04606303CT.gov A Phase Ⅱ Trial of Neoadjuvant Toripalimab Plus Platinum-doublet Chemotherapy in Locally Advanced NSCLC. | — | Unknown | — | — | — |
NCT04613804CT.gov Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy | — | Unknown | — | — | — |
NCT04238169CT.gov Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC | — | Completed | — | — | — |
NCT04459663CT.gov JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy. | — | Unknown | — | — | — |
NCT04374877CT.gov Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT04158440CT.gov Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC | — | Active Not Recruiting | — | — | — |
NCT04316351CT.gov Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance | — | Unknown | — | — | — |
NCT04313660CT.gov Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study | — | Unknown | — | — | — |
NCT04144608CT.gov Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC | — | Completed | — | — | — |
NCT04304248CT.gov Neoadjuvant Toripalimab Plus Platinum-based Doublet for Stage III Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04193098CT.gov Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC | — | Unknown | — | — | — |
NCT03924050CT.gov Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI | — | Unknown | — | — | — |
NCT03848611CT.gov CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC). | — | Unknown | — | — | — |
NCT03856411CT.gov A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC | — | Completed | — | — | — |
NCT03732664CT.gov ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer | — | Completed | — | — | — |
NCT03513666CT.gov A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment | — | Completed | — | — | — |
NCT03301688CT.gov The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001 | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Toripalimab (this asset) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P3 | B · 63 |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Veliparib | AbbVie | P3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Zoledronate | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P4 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Avitinib | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | P3 | BBB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Toripalimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P3 | BB · 67 |
| Extranodal Nasal NK/T Cell Lymphoma | — | P3 | BB · 66 |
| Small Cell Lung Carcinoma | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Toripalimab in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 9, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/toripalimab-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →